RVLP News and Press, RVL Pharmaceuticals plc From 10/06/23

2023-10-06 08:29:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Omniq (NASDAQ: OMQS ) stock is taking a beating on Friday after the artificial intelligence ( AI ) company announced a public share offering . According to a press r...

2023-10-06 07:29:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off Friday with a breakdown of the biggest pre-market stock movers traders need to know about! Moving stocks this morning are insider buying, reports of a big acquisit...

2023-10-02 07:27:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking on Monday as we start off the week with all the latest news! Moving stocks this morning are shareholder meetings, a bankruptcy filing and more. ...

2023-09-29 10:06:05 ET DENVER, Colo., Sept 29, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SeaStar Medical Holding (NASDAQ: ICU), Structure Therapeutics (NASDAQ: GPCR), Novo Integrated Sciences (NASDA...

2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in...

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose UPNEEQ(R) is available through RVL Ph...

RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food an...

RVL Pharmaceuticals’ CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year’s H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and...

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(...